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Marc Feldmann, Fionula M. Brennan, leads to a pro-inflammatory response remains to be
and Ravinder N. Maini determined. To obtain clues about the important anti-
Kennedy Institute of Rheumatology gens recognized, T cell receptor expression in RA joints
Hammersmith has been extensively studied, but early reports of re-
London, W6 8LW stricted T cell receptor usage have not been confirmed.
United Kingdom The nature of the autoantigens recognized by autoanti-
gen reactive T cells in rheumatoid arthritis are not
known, although collagen type II (Ronnelid et al., 1994),
a major protein of hyaline cartilage, and other chondro-Rheumatoid arthritis (RA) is a common human autoim-
cyte/cartilage proteins, as well as the heat shock proteinmune disease with a prevalence of about 1%. While
HSP70 have been suggested. Much progress will be-there has been progress in defining its etiology and
come possible when the important T cell epitopes arepathogenesis, these are still incompletely understood
defined, as it will open up the possibility of inducing(Ziff, 1990). Like many autoimmune diseases it is more
antigen specific therapy, such as immunological tol-frequent in women, suggesting a role for sex hormones.
erance.Rheumatoid arthritis is characterized by a chronic in-
However, the role of T lymphocytes in established RAflammation of the synovial joints and infiltration by
is incompletely understood. Based on the lack of T cellblood-derived cells, chiefly memory T cells, macro-
phages, and plasma cells, all of which show signs of proliferation and low levels of T cell derived cytokines
activation, (Janossy et al., 1981; Cush and Lipsky, 1988). detectable in RA joints, Firestein and Zvaifler (1990) sug-
This leads in most cases to progressive destruction of gested that T cells may not be important in perpetuating
cartilage and bone, which occurs after invasion of these disease at the late stages. This possibility is supported
tissues by the cellular synovial tissue and is believed to by the disappointing results of therapeutic trials of
be mainly mediated by cytokine induction of destructive agents designed to diminish T cell function in late-stage
enzymes, chiefly matrix metalloproteinases. There is RA patients: depleting antibodies to CD4, CDW52, and
also prominent development of new vessels and evi- CD7, as well as immunotoxins directed to IL-2 receptor
dence of systemic inflammation, for example, upregu- or CD5 expressing cells (e.g., van der Lubbe et al., 1995;
lated acute phase proteins. In more severe cases there Kirkham et al., 1992; Moreland et al., 1995; Olsen et
is involvement of vessels and other organs. Mortality is al., 1994) have only yielded moderate or no benefit in
increased in patients with severe rheumatoid arthritis placebo controlled studies. Since there are two major
(Pincus and Callahan, 1993). A diseased joint showing subsets of of helper (CD41) T cell function (Th1 cells
the major cell types and sites of joint destruction is producing the pro-inflammatory mediators IL-2 and
illustrated in Figure 1. IFNg and Th2 cells producing IL-4, which has anti-in-
flammatory properties [Mosmann and Coffman, 1989]),
The Role of T and B Lymphocytes it is possible that nonspecific T cell directed immuno-
Twin and other genetic studies have demonstrated that therapy, such as those listed above, may be ineffective
a major genetic contribution to disease predisposition because both pathogenic and protective T cell functions
resides in the HLA-DR locus (Stasny, 1978). More than would be downregulated.
80% of caucasian rheumatoid patients express DR1 or In view of the clear cut role of T cells in driving immune
DR4 subtypeswhich share an epitope mapping to amino responses and in animal models of autoimmunity, in-
acids 70-74 of the DRb chain, in the polymorphic region cluding the collagen type II and other models of arthritis,
lining the peptide binding groove (Gregersen et al.,
1987). As the only known function of DR is to present
peptides to CD41 T cells, this genetic association
clearly implicates a role for T cells at some stage in the
disease pathogenesis. However, it is not known which
stage that may be. It could be in defining the T cell
repertoire of antigen receptors or in the presentation of
an inducing extrinsic antigen (e.g., pathogen) involved
in the induction of the disease process. However, the
most popular concept is that the pathogenic role for
CD41 T cells is in presentation of an autoantigen (Todd
et al., 1988). There is recent evidence that the genetically
susceptible HLA-DR4 (e.g., DR0401) alleles bind differ-
ent peptides in their peptide binding groove than the
nonsusceptible (e.g., DR0402) alleles. Susceptible al-
leles bind a negatively charged amino acid at the p4
pocket of the binding groove, (Woulfe et al., 1995). Muta-
tion analysis revealed that position 71 of the DRb chain
in particular correlates with the genetic linkage of RA Figure 1. Rheumatoid Joint Indicating Major Cell Types and Sites
of Joint Destructionsusceptibility (Hammer et al., 1995). How this eventually
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it is on balance likely that T cells are involved both in
disease induction and in disease maintenance. The most
likely reason for their reduced function in active disease
is the inhibitory cytokine environment, with augmented
IL-10 and TGFb (Fava et al., 1989; Wahl, 1994; Katsikis
et al., 1994).
The role of B lymphocytes in RA has been extensively
studied since the discovery that most patients have IgM
autoantibodies termed rheumatoid factors (RF) which
recognize the Fc region of IgG. However, RF are not
present in all RA patients and are also present in other
Figure 2. Figure 2. Cytokine Cascade in Rheumatoid Arthritis
diseases, such as Sjogren's syndrome. The DNA se-
quences encoding RF have been extensively studied to
seek clues concerning the pathogenesis of RA. Both TNFa would also diminish the actions of many other
IgM and the less frequent IgG RF differ from the germ pro-inflammatory mediators, and hence, that TNFa may
line sequence, the latter extensively, suggesting the be a good therapeutic target.
presence of an antigen driven process (Olee et al., 1992). Analogous studies have evaluated the expression of
How RF factor contributes to the disease process is still anti-inflammatory cytokines in rheumatoid joints. TGFb
not understood, but current concepts include a role in is abundant, both in latent and active form (Fava et al.,
facilitating antigen presentation. Immune complexes of 1989; Wahl, 1994), as is IL-10 (Katsikis et al., 1994). In
RF and IgG may contribute to disease activity by activat- contrast, IL-4 is not usually found, suggesting that the
ing complement and stimulating cytokine synthesis. T cells involved in RA joints are chiefly of the Th1 type.
Augmented numbers of CD51 B lymphocytes have been Cytokine inhibitors such as the IL-1 receptor antagonist
detected in patients with RA (Plater-Zyberk et al., 1985). and soluble TNF receptors are also upregulated in rheu-
Abnormal glycosylation of IgG in active RA has been matoid joints (reviewed by Feldmann et al., 1996). Cur-
reported and may be important because it would favor rent views of the cytokine network in rheumatoid joints,
immune complex formation. Other autoantibodies are and probably in other chronic inflammatory sites, thus
also present in RA, including those reacting to filaggrin involve two key concepts. First, that TNFa is at the apex
(Sebbag et al., 1995). of a pro-inflammatory cytokine cascade, as illustrated
simplistically in Figure 2. Second, that in a chronic in-
flammatory site there is also upregulation of multiple
Role of Cytokines in Rheumatoid Arthritis anti-inflammatory mediators. Hence the rheumatoid sy-
As cytokines are important mediators of the immune novium can be envisaged as an equilibrium, just tilted
and inflammatory systems, establishing their role in au- towards the pro-inflammatory side (Figure 3). A TNFa
toimmune diseases was of interest, especially in view dependent cytokine cascade is also found in normal
of the hypothesis we had proposed in 1983 which linked immune responses, such as in experimental gram nega-
cytokine induced upregulation of antigen presentation tive infections, in which blocking TNFa also reduced
to the development of autoimmunity. For this purpose IL-1 and IL-6 expression (Fong et al., 1989).
RA, with its accessible lesions, was the ideal disease
study. Several groups, including our own, have investi- Animal Models of Arthritis
gated cytokine mRNA and protein expression in synov- Injecting genetically susceptible strains of mice with
ium (e.g., Di Giovine et al., 1988; reviewed by Firestein cartilage constituents such as collagen type II in com-
and Zvaifler, 1990; Arend and Dayer, 1995; Feldmann et plete Freund's adjuvant induces an arthritis with synovi-
al., 1996). Despite differences in duration, severity of tis and erosionshistologically resembling RA (Courtenay
disease, or treatment, all RA operative samples and et al., 1980). Both T cell and B cell activation is important
biopsies expressed the same broad range of pro-inflam- in collagen induced arthritis. Cytokinesof bothTh1 (IFNg
matory cytokines, suggesting that synovial cytokine ex- secreting) and Th2 cells (IL-4 secreting) are produced,
pression in a diseased tissue was prolonged, unlike the and at disease onset a Th1 profile predominates. By
transient cytokine production induced by mitogen. This serendipity, another informative model of arthritis was
hypothesis was tested by enzymatically dissociating sy- developed by G. Kollias and colleagues (Keffer et al.,
novium and culturing the cells without extrinsic stimula- 1991). A human TNFa transgene was generated in which
tion. These cultures produced cytokines such as IL-1
and TNFa for a prolonged period of time, indicating that
the signals driving cytokine production were present,
and so could be studied in vitro. By adding anti-TNFa
antibodies, it was found that synovial production of
other pro-inflammatory cytokines such as IL-1 (Brennan
et al., 1989), GM-CSF, IL-6, and IL-8 was greatly re-
duced. Blocking IL-1, using the IL-1 receptor antagonist
reduced IL-6 and IL-8 production, but not that of TNFa
(reviewed by Feldmann et al., 1996). These results indi-
cated that the pro-inflammatory cytokines were linked
in a network or cascade. It suggested that blocking Figure 3. Cytokine Disequilibrium in Rheumatoid Arthritis
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the AU rich 39 UT region (which shortens mRNA half life) benefit because of diminished cell recruitment into joints
(Maini et al., 1995).was replaced by the stable b globin 39 UT, resulting in
overexpression of TNFa. Multiple lines of these mice However, anti-TNFa therapy of rheumatoid arthritis is
not a cure, and other therapeutic approaches arewere found to develop a chronic erosive arthritis. This
transgenic model directly demonstrates the concept needed. In collagen induced arthritis in DBA/1 mice,
there is marked synergy between anti-TNF antibodythat TNFa is of importance in the arthritic process, as
does the therapeuticbenefit of treatment with anti-TNFa therapy and therapy targeted at T cells, for example
with anti-CD4 antibody, suggesting that synergistic ap-antibody in the DBA/1 collagen induced arthritis model
(Thorbecke et al., 1992; Williams et al., 1994). Subse- proaches targeting these two key aspects of the patho-
genesis may be the best approach towards attemptingquently it has been found that virtually all animal models
of arthritis are ameliorated by anti-TNFa, including hu- a cure (Williams et al., 1994).
man-TNFa transgenic arthritis, adjuvant arthritis, strep-
tococcal cell-wall arthritis, and antigen induced arthritis
Unresolved Issues
in rabbits (reviewed by Feldmann et al., 1996). Histologi-
There is much yet to learn about the etiology, pathogen-
cal analysis has demonstrated that anti-TNFa therapy,
esis, and therapy of rheumatoid arthritis. For example,
after disease onset protected the joints from destruction
the non-HLA genetic predisposition, which may include
induced by the inflammatory process (e.g., Williams et
cytokine polymorphism and a tendency to generate rela-
al., 1994).
tively too many Th1 cells, may yield new clues for ther-
apy. There is debate as to whether the process of joint
destruction is directly driven by the inflammatory pro-Immunotherapy of Rheumatoid Arthritis
cess, or whether the basic process of joint destruction,The downregulation of pro-inflammatory cytokines by
with proliferation of fibroblasts and other cells is drivenanti-TNFa antibody in RA joint cultures in vivo and the
independently. Certainly in the animal models, anti-benefit of anti-TNFa in collagen induced arthritis pro-
TNFa prevents or abrogates joint destruction, sug-vided the rationale for clinical trials of anti-TNFa anti-
gesting that inflammation and joint destruction arebody in longstanding RA patients with active disease.
linked. What drives the production of the excessiveThe results of multiple clinical trials of anti-TNFa anti-
TNFa in RA joints and why the anti-inflammatory mecha-body performed with cA2, a chimeric anti-TNFa anti-
nisms cannot fully downregulate its effects are tantaliz-body (mouse Fv, human IgG1), have revealed a marked
ing questions. What is the major cause of new capillarybenefit in all assessable aspects of the disease. There
growth (neovascularization) needed to sustain the aug-was very rapid improvement, within days, and for an
mented cell mass in the synovium? As unravelling theantibody the benefit lasted a long time, ranging from
pathogenesis of RA has already led to therapeutic ad-8-26 weeks in the first trial (Elliott et al., 1993). After
vances, it is very likely that answers to the remainingthese patients relapsed, retreatment with cA2 on further
questions will help generate new treatment approaches.occasions ameliorated disease on each occasion, indi-
cating that the pro-inflammatory cascade remains TNFa
dependent. The clinical efficacy of anti-TNFa has been
verified in randomized double-blind placebo-controlled References
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